Shanjixinzhipu completed a seed round financing of tens of millions of yuan, defining the next generation of ultrasensitive proteomics analysis with "semiconductor + AI"
Recently, Shenzhen Grid Core Bio - Technology Co., Ltd. (hereinafter referred to as "Grid Core" or "the Company") announced the completion of a seed - round financing of tens of millions of yuan. This round of financing was led by the Seed Fund of Shenzhen Capital Group, with joint investments from Nanshan Strategic Emerging Industry Investment and Guangming Taino Seed Fund. The financing funds will be mainly used to accelerate the R & D and industrialization process of the Company's AI - driven high - throughput and ultrasensitive proteomics bioanalysis platform, promote the certification process of relevant instruments and reagents, and further expand the team and technology layout in the fields of drug development and clinical diagnosis.
Grid Core was founded in June 2023 by international top - level professionals in the field of biochip material science, in collaboration with senior experts in the AI algorithm and life - science instrument industries. The Company is committed to deeply integrating advanced semiconductor technology and artificial intelligence into the field of bioanalysis, focusing on the technological development of a new - generation ultrasensitive proteomics platform. Its core goal is to provide efficient, accurate, and low - cost intelligent solutions for upstream life - science research, new drug R & D, and clinical diagnosis, and to promote the transition of protein detection technology from traditional optics to semiconductor digitalization and AI intelligence at the platform level.
Grid Core has laid out dozens of patents around its core technologies and products, and the certification process of relevant instruments and reagents is progressing steadily. The Company's technology has been verified to achieve highly sensitive detection of femtogram - level protein markers in blood samples, and it has significant differentiated advantages over foreign similar products in terms of cost control, test stability, equipment integration, and intelligence level.
One of the Company's core technologies is the Integrated Surface Array Sensing System (ISAS). ISAS adopts a 1:1 on - chip fluorescence imaging technology, which not only has significant advantages such as a large field of view, high integration, and one - key automatic imaging, but also significantly reduces the cost of the instrument and greatly shrinks the equipment volume. It can directly replace the expensive and complex traditional fluorescence microscopic imaging module, laying a solid technological foundation for the popularization and miniaturization of high - end bioanalysis instruments and can be widely extended to various high - end fluorescence imaging scenarios.
Schematic diagram of ISAS imaging
In the construction of the ultrasensitive protein analysis platform, Grid Core has achieved the world's first deep integration of "microfluidic droplets + semiconductor on - chip imaging + AI computational optics". It not only ensures the accurate detection with femtogram - level sensitivity and is superior to international leading products in terms of accuracy and stability, but also provides highly reliable data consistency guarantee for pharmaceutical companies in long - cycle drug development and multi - center clinical trials.
Diagram of the ultrasensitive protein analysis platform
With the completion of this round of financing, Grid Core will fully accelerate the dual breakthroughs in underlying technology and application scenarios. On the semiconductor side, the Company will promote the iteration of the ISAS system to version 2.0 to further increase the data collection density; on the core AI algorithm side, the Company will focus on the in - depth R & D of the "AI intelligent bioanalysis brain". It will construct a noise - reduction algorithm capable of adaptively identifying complex background noise and develop intelligent program expansion technology to achieve automatic AI quality control and abnormal early warning for the entire experimental process.
In addition, the Company will actively promote the application of this platform in drug R & D in fields such as neurodegenerative diseases, autoimmunity, and tumor immunity, and deeply participate in the key links of target discovery and efficacy evaluation, aiming to provide global pharmaceutical companies with a one - stop intelligent solution from biomarker screening to companion diagnosis.
Zhang Qingyang, the founder of Grid Core said: "The completion of this round of tens of millions of yuan in financing is an important milestone in the Company's development. We are grateful for the leading investment of the Seed Fund of Shenzhen Capital Group and the joint support of Nanshan Strategic Emerging Industry Investment and Guangming Taino Seed Fund. We firmly believe that future bioanalysis is not just about data acquisition, but also about the discovery of insights. Grid Core will take this as an opportunity to accelerate the integration of cutting - edge semiconductor sensing technology and generative AI algorithms into life - science detection, create 'intelligent instruments that understand bioanalysis', empower global pharmaceutical companies and research institutions, and contribute Chinese strength to promoting precision medicine and new drug development."
The Nanshan Strategic Emerging Industry Investment team said: "Grid Core is an early - stage technology project that is key - supported under the 'Six - in - One' innovation and entrepreneurship action plan of Nanshan District. Grid Core deeply integrates semiconductor technology with biological detection, and its Integrated Surface Array Sensing System (ISAS) has clear originality and industrial breakthrough potential, which is highly in line with the strategic direction of Nanshan District to cultivate new productive forces and build a first - class innovation ecosystem. We look forward to supporting the Company's growth in Nanshan through multi - dimensional empowerment of funds and policies, and jointly promoting the high - quality development of the regional life - science industry."
The Guangming Taino Seed Fund team said: "We highly recognize Grid Core's underlying technological innovation in the direction of 'AI - driven life and health'. Grid Core deeply integrates semiconductor sensing with protein detection, and its ISAS system has clear originality and platform value, which fully conforms to our key investment direction of 'IT + BT'. We always believe that empowering value is greater than capital support. Taino will give full play to its constructed ecological empowerment system to help the Company move from technology verification to industrial implementation, and jointly build a globally competitive brain - health innovation platform."
This article is from the WeChat official account "Nanshan Strategic Emerging Industry Investment", and is published by 36Kr with authorization.